Apart from systemic approaches to target the AhR, GI-selective modulation poses safety concerns, including enhanced susceptibility to infection and reduced bacterial infection clearance [120], impaired mucosal immunity [121,122], antibiotic resistance [123], attenuation or exacerbation of inflammation [124], and increased cancer risk from generation of procarcinogens [93,125]. This evidence concerns the gene AHR and cancer.